There’s a sentiment that a book finds you at the right time in your life. Sometimes, when you have a chronic illness like pulmonary hypertension (PH), that book finds you when you’re sitting on a bench outside of a hospital. Recently, that book for me was “Famesick,”…
Discussion
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IKT-001, an experimental formulation of imatinib that Inhibikase Therapeutics is developing to treat pulmonary arterial hypertension (PAH). The FDA gives orphan drug designation to investigational medications that aim to treat rare diseases, defined as conditions…
Discussion
COVID-19 and pulmonary arterial hypertension (PAH) may share molecular mechanisms that could explain common disease-related features, a study reported. According to researchers, the findings provide a framework for exploring disease mechanisms and prioritizing future therapeutic strategies that target overlapping mechanisms of both conditions. The study, “Network-Based Multiomics Integration…
Discussion
People with pulmonary arterial hypertension (PAH) have less diversity among the viruses that infect bacteria in their digestive tracts, according to a new study. These findings add to a growing body of research suggesting that the gut microbiome — the community of bacteria, viruses, and other microscopic organisms…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
